man sight on white microscope

About Us

Renovaro Biosciences is driven by a steadfast commitment to revolutionize healthcare.

What we do

Renovaro Biosciences is driven by a steadfast commitment to revolutionize healthcare.

Our primary goals encompass pioneering advancements in biotechnology to develop groundbreaking therapies and diagnostic tools.

We aim to address unmet medical needs in diverse areas such as oncology, neurology, infectious diseases, and rare genetic disorders.

a future free from toxic chemo- therapy

Our goals

By fostering global collaborations, we seek to accelerate the translation of scientific breakthroughs into tangible solutions, positively impacting lives worldwide.

Renovaro is dedicated to creating a healthier and more resilient future for humanity through innovation, ethical practices, and a relentless pursuit of excellence in biotechnology.

Our latest news

More news
Statement of Renovaro Inc

February 14, 2024

Statement of Renovaro Inc

We felt compelled to comment on the shorter Hindenburg’s opinion piece.

Cutting Edge AI Company GEDiCube and Cyclomics sign binding LOI to join forces and position themselves at the forefront of the global liquid biopsy marketplace

February 13, 2024

Cutting Edge AI Company GEDiCube and Cyclomics sign binding LOI to join forces and position themselves at the forefront of the global liquid biopsy marketplace

A Binding LOI has been executed: GEDiCube will acquire 75% of Cyclomics at Closing.

AI Pioneer GEDiCube and Biotech Innovator Renovaro Biosciences Combine Forces to Accelerate Personalized Medicine

February 13, 2024

AI Pioneer GEDiCube and Biotech Innovator Renovaro Biosciences Combine Forces to Accelerate Personalized Medicine

“We believe this combination marks a significant milestone in the journey of personalized medicine,”

Results Shareholders Meeting

January 25, 2024

Results Shareholders Meeting

All of the matters put forward before the Company’s shareholders for consideration and approval, as set out in the Company’s definitive proxy statement dated January 3, 2024, were approved by the requisite number of votes cast at the meeting.

Button

Executive Management

Simon Tarsh

Simon Tarsh

Interim CFO

The Honorable Mark Dybul, MD

The Honorable Mark Dybul, MD

Chief Executive Officer & Director